Y

esterday, I brought you the nice. Today, it’s the naughty: the nominees for the worst biopharma CEO of 2017.

Even in a good year for biopharma, there’s always a crop of CEOs, through their actions or words, who manage to screw up badly enough to make the rest of us cringe. Or get angry. I always have fun compiling this list of bungling biopharma CEOs. And here they are. You’ll get a chance to vote at the bottom of this post.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • CytRx is notable as one of the very few penny stocks that has been used more than once as a pump-and-dump vehicle by Howard Appel and Mark Tompkins, both stock fraud recidivists. Most stocks they exploit are left for ruin after one round. But go through past years of penny-stock promoters’ newsletters, and you’ll find that CytRx gets the fraud treatment a few times over the years. This company has never had any actual concrete drug development plans.

  • None of this compares to the escalation of the drug war, now enlarging the front against people in pain. The war supported by STAT.

  • This is the total embodiment of greed and the absolute greed of our “health care system”.
    Such is the concern of our Congress. Personal gain; certainly not the welfare of our people.
    We have become a society of greed with no concern of the overall good.
    Sad, but TRUE

  • Interesting that Fleming Ornskov of Shire who sat there watching more than $30B of market cap evaporate would not be on top of this list.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.